Evidence map›Paper›PMID 41954340›Full record

ReviewPathologica2025

Next-generation sequencing methodologies to identify patients for targeted therapy: focus on HR+/HER2- metastatic breast cancer.

Umberto Malapelle, Simonetta Buglioni, Isabella Castellano, Carmen Criscitiello, Giuseppe Curigliano, Giulia d'Amati, Carmine De Angelis, Dario de Biase, Francesco Pepe, Giuseppe Perrone and 5 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pathologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. The journal of liquid biopsy · 2026
    Review
  2. Liquid biopsy in solid tumours: expert opinion paper of the European society of pathology.Virchows Archiv : an international journal of pathology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Umberto MalapelleDepartment of Public Health, University Federico II of Naples, Naples, Italy.
Simonetta BuglioniDepartment of Pathology, IRCCS National Cancer Institute Regina Elena, Rome, Italy.
Isabella CastellanoDepartment of Medical Sciences, University of Turin, Turin, Italy.
Carmen CriscitielloDepartment of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Giuseppe CuriglianoDepartment of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Giulia d'AmatiDepartment of Radiological, Oncological and Pathological Sciences, Sapienza-University of Rome, Rome, Italy.
Carmine De AngelisClinical and Translational Oncology, Scuola Superiore Meridionale, Naples, Italy.
Dario de BiaseDepartment of Pharmacy and Biotechnology (FABIT), University of Bologna, Bologna, Italy.
Francesco PepeDepartment of Public Health, University Federico II of Naples, Naples, Italy.
Giuseppe PerroneOperative Research Unit of Anatomical Pathology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.
Cristian ScatenaDivision of Pathology, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
Maria ScatoliniMolecular Oncology Laboratory, Fondazione Edo ed Elvo Tempia, Ponderano, Biella, Italy.
Dario TrapaniDepartment of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Konstantinos VenetisDivision of Pathology, European Institute of Oncology IRCCS, Milan, Italy.
Nicola FuscoDepartment of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alterations in the phosphoinositide 3-kinase (PI3K)/AKT/PTEN signaling pathway are a well-recognized mechanism of resistance in hormone receptor-positive, HER2-negative metastatic breast cancer (HR+/HER2- mBC). These alterations are present in approximately half of patients with HR+/HER2- mBC. The major alterations in the pathway are somatic mutations in the

Indexed as

Biomarkers, TumorBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesHigh-Throughput Nucleotide SequencingMolecular Targeted TherapyClass I Phosphatidylinositol 3-KinasesFemaleHumansMutationPTEN PhosphohydrolaseReceptors, EstrogenReceptors, ProgesteroneSignal TransductionBiomarkers, TumorClass I Phosphatidylinositol 3-KinasesERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesPTEN PhosphohydrolaseReceptors, EstrogenReceptors, Progesteronemetastatic breast cancerNext-generation sequencingPI3K pathwaysomatic mutation

Identifiers

PMID41954340
PMCPMC13094335

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.